CD274 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: It is unclear if tRCC is sensitive to checkpoint inhibitor therapy despite a relatively frequent PD-L1 expression as there are no prospective studies specifically in this population.